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Prostate cancer (CaP) is the most common adult male cancer in the
developed world. The paucity of biomarkers to predict prostate
tumor biology makes it important to identify key pathways that
confer poor prognosis and guide potential targeted therapy. Using
a murine forward mutagenesis screen in a Pten-null background,
we identified peroxisome proliferator-activated receptor gamma
(Pparg), encoding a ligand-activated transcription factor, as a pro-
moter of metastatic CaP through activation of lipid signaling path-
ways, including up-regulation of lipid synthesis enzymes [fatty acid
synthase (FASN), acetyl-CoA carboxylase (ACC), ATP citrate lyase
(ACLY)]. Importantly, inhibition of PPARG suppressed tumor growth
in vivo, with down-regulation of the lipid synthesis program. We
show that elevated levels of PPARG strongly correlate with elevation
of FASN in human CaP and that high levels of PPARG/FASN and PI3K/
pAKT pathway activation confer a poor prognosis. These data sug-
gest that CaP patients could be stratified in terms of PPARG/FASN and
PTEN levels to identify patients with aggressive CaP who may re-
spond favorably to PPARG/FASN inhibition.
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Prostate cancer (CaP) is now the most common male cancerand second leading cause of cancer mortality in the developed
world (1). The majority of patients are likely to die with, rather than
from, CaP, making it important to identify key pathways that confer
poor prognosis, thus minimizing overtreatment.
The PTEN (phosphatase and tensin homolog deleted on
chromosome 10) tumor suppressor gene (TSG), a key element
of the PI3K pathway, is implicated in numerous human cancers
(2). The PI3K pathway is altered in ∼25–70% of CaP and vir-
tually all metastatic tumors (3, 4). Homozygous Pten deletion in
the mouse prostate leads to prostatic intraepithelial neoplasia
(PIN) at 12 wk of age and invasive carcinoma after 6–9 mo (5),
with the long latency suggesting additional mutations are re-
quired for disease progression. Several genes cooperate with
Pten loss to induce tumorigenesis in mice, including either loss
of tumor suppressors such as Smad4 or Tp53 or activation of
Erbb2 or Erg. However, none of these tumors fully reflect the
continuum of human CaP (6–9).
Despite significant investments in clinical biobanks, next-
generation sequencing, and other “omic” approaches, the het-
erogeneity and multifocal nature of CaP means that most of
these technologies have not produced conclusive findings to in-
form on disease outcome, with large sample numbers and an
extended follow-up required for statistical significance (4, 10). As
a result, multiple genes/pathways involved in CaP have been
isolated, with difficulties in identifying the “driver” events from
more common background “passenger” mutations. Thus, novel
approaches to induce somatic mutagenesis have been developed
to identify the key genes that drive metastatic CaP in vivo. One
method is to use the synthetic Tc1/mariner family transposon-
based Sleeping Beauty (SB) approach (11). The SB system uses
independent transgenes carrying the transposon (T2Onc3) and the
enzyme transposase to initiate transpositions and thus ransom
somatic mutagenesis. After integration, the transposon may dis-
rupt the expression of TSGs in neighboring sequences or over-
express nearby full length/truncated oncogenes, using its promoter/
splice donor site. The expression of the transposase can be ubiq-
uitous or tissue specific (using Cre-recombinase driven by tissue
specific promoters). The SB model system has been used success-
fully to determine low-frequency somatic mutations that are drivers
of tumorigenesis (12), which is relevant in human CaP, because
recent large-scale sequencing demonstrates somatic mutations are
relatively rare compared with other malignancies (3).
To our knowledge, this is the first report showing acceleration
of prostate tumorigenesis in a Sleeping Beauty system. We vali-
date the feasibility of such a screen in a background of PtenNull-
driven CaP and demonstrate the oncogenic role of the lead
candidate, namely peroxisome proliferator-activated receptor
gamma (Pparg) in both murine and human CaP.
Results
Identification of Genes from a SB Transposon Screen on a Background
of PtenNull-Driven Prostate Cancer. PtenNull (PB-Cre4:Ptenfl/fl) mice de-
velop CaP after a long and variable latency, providing an op-
portunity to characterize genes that cooperate with Pten loss to
promote prostate tumorigenesis. We previously demonstrated
that these PtenNull mice develop high-grade prostatic intra-
epithelial neoplasia (HGPIN) at 3 mo, with a slow progression
to overt CaP (>10 mo), with no metastasic development up to
18 mo (6).
We hypothesized that an insertional mutagenesis approach
could directly identify “driver” genes in the development of lethal
CaP. Accordingly, we interbred our PtenNull model with the T2/
Onc3 transposon SB system, with a CMV enhancer/chicken β-actin
(CAG) promoter to drive transposition through epithelial-specific
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expression (13). Male mice with appropriate SB genotype:
Sleeping Beauty PtenNull referred to as SB:PtenNull (PB-Cre4
Ptenfl/flT2/Onc3hetRosa26Lox66SBLox71/+) and littermate con-
trols [PtenNull (PB-Cre4:Ptenfl/fl) and SBControl (T2/Onc3het
Rosa26Lox66SBLox71/+)] were generated (Fig. 1A) and housed as
previously described (11, 14). The SB:PtenNull mice (n = 21) were
monitored for tumor development, and all these mice, along with
relevant controls, were available for full necropsy and tissue
harvesting once the mice reached clinical end points (a combi-
nation of tumor palpability, blood in urine, and murine hunching
and shortness of breath) (6). In summary, SB:PtenNull mice exhibi-
ted significantly accelerated prostate tumorigenesis compared with
the PtenNull cohort (median, 293 vs. 469 d; log-rank, P < 0.0001;
Fig. 1B), with an increase in tumor size (mean, 9.1 vs. 2.9 g; Mann–
Whitney, P = 0.002; Fig. 1 C and D) secondary to increased pro-
liferation as demonstrated by Ki-67 expression (n = 21 vs. 21,
positive cells/high powered field (20×); Mann–Whitney, P <
0.0001; Fig. 1E and Fig. S1A). We also observed a loss in conti-
nuity of p63 immunoreactivity, a basal cell marker, in the SB:
PtenNull tumors, compared with the PtenNull controls, consistent
with increased levels of invasion (Mann–Whitney, P < 0.0001; Fig.
1F and Fig. S1D) (6). SB:PtenNull mice had an increased frequency
of metastasis to lungs (6/21 vs. 0/21; two-tailed Fisher exact, P =
0.0207) and lymph nodes (pelvic/para-aortic chain, the primary
lymphatic landing site for tumor cells from the prostate; 15/21 vs.
3/21; two-tailed Fisher exact, P = 0.0004) compared with PtenNull
controls (Fig. 1G and Table 1).
Common insertion sites (CISs) were identified from the
SB:PtenNull cohort; those CISs also found in the control co-
hort (SBControl) were not analyzed further. Fifty-three genes harboring
unique CIS were found to be statistically significant by chromosomal
analysis, with Gaussian kernal correlation (GKC)-adjusted P <
0.05; among these genes, 10 were significant by genome-wide
analysis (GKC P value adjusted across genome, P < 0.05; Dataset
S1). To identify candidate genes driving aggressive/metastatic
disease, we interrogated the data according to the tumor weight
and the presence or absence of lung and/or lymph node in-
filtration (Dataset S2). Based on these criteria, we identified Pparg
(isoform 1), encoding a critical regulator of lipid metabolism, as a
gene of interest with dramatic synergy to Pten-mediated prostate
carcinogenesis. Insertions within the Pparg gene (PpargINT) (n = 8
mice) were associated with larger tumors compared with tumors
with non-Pparg CISs (referred to as PpargWT) (n = 13 mice;
Mann–Whitney, P = 0.0339). In mice bearing tumors with Ppar-
gINT, there was a significant association with the presence of me-
tastases affecting lung or (pelvic/para-aortic) lymph nodes (two-
tailed Fisher’s test, P = 0.0139 and 0.0046, respectively). Of in-
terest, there were two separate significant hotspots of insertion of
the transposon into the Pparg gene (Dataset S3). All of the
PpargINT were upstream of the start codon, with the transposon
aligned in the forward direction (splice donor/promoter align-
ment), strongly suggesting that they would act to increase gene
transcription (Dataset S3). Given all of the above evidence, we
decided to further investigate the role of Pparg as a potential
oncogene in CaP.
Pparg Activation and Pten Loss Cooperate to Drive Murine and
Human CaP with Associated Alteration in Lipid Metabolism. Using
quantitative RT-PCR to analyze the expression of Pparg1 in
prostate tumors from representative mice with PpargINT, Pparg1
mRNA was found to be elevated 10-fold in PpargINT [SB:PtenNull
with Pparg insertion; selected based on insertion site (both hot-
spots represented)] tumors compared with PpargWT (SB:PtenNull
without Pparg insertions; selected based on tumor size and age of
death to represent phenotype of cohort) and PtenNull tumors
(Fig. 2A). The status of PPARG expression was studied, dem-
onstrating an increase in PPARG protein levels, by immuno-
blotting and immunohistochemistry (IHC) analyses (Fig. S1 G–I
and Fig. 2 B and C), and up-regulation of its key lipogenic target
enzyme fatty acid synthase (FASN) (Fig. 2 B, D, and E and Fig.
S1 J–L) at protein and mRNA levels. In addition, acetyl-CoA
carboxylase (Acc) and ATP citrate lyase (Acly), two further re-
lated targets of PPARG, were also up-regulated at the mRNA
level (Fig. 2D) in PpargINT prostate tumors.
RNA-sequencing (RNA-Seq) from representative PpargINT
and PpargWT tumors (n = 3 vs. 3; selected as above) was carried
out to study the molecular drivers in SB:PtenNull tumors har-
boring Pparg insertions. To confirm that PpargWT tumors were
an appropriate control cohort, we carried out further analysis
comparing PpargINT vs. PpargWT and PpargINT vs. PtenNull, re-
spectively, and found an excellent correlation between the two
analyses (R = 0.848; Fig. S2). Specifically, Pparg and the related
Ppargc1b mRNA expression were up-regulated in PpargINT tu-
mors (Fig. S3A). Pathway enrichment analysis identified “Tran-
scriptional control of cholesterol and fatty acid biosynthesis” as
the top pathway overrepresented in the PpargINT tumors vs.
PpargWT tumors (P = 0.0022; Dataset S4). The same pathway
ranked third in the enrichment analysis for PpargINT vs. PtenNull
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Fig. 1. Identification of novel genes from a SB transposon screen on a
background of PtenNull-driven prostate cancer. (A) Breeding schedule
to generate SB:PtenNull (PB-Cre4:Ptenfl/flT2Onc3het Rosa26Lox66SBLox71/+).
(B) Kaplan–Meier (log-rank) curve demonstrating reduced survival in the
SB:PtenNull cohort, compared with the PtenNull mice (n = 21 vs. 21, P <
0.0001). (C) Boxplot comparing the weight of primary prostate tumors (n =
21 vs. 21, *P = 0.002; Mann–Whitney). (D) Prostate tumor from SB:PtenNull
mice. (E ) Boxplot comparing Ki-67 staining between the cohorts (n = 21 vs.
21, *P < 0.0001; Mann–Whitney). (F ) Comparison of p63 IHC between the
cohorts (y axis represents percentage of glandular basement left intact;
n = 21 vs. 21 *P < 0.0001; Mann–Whitney). (G) Representative lung me-
tastasis from SB:PtenNull mouse.
Table 1. Number of mice showing evidence of metastases in
lung and lymph nodes
Site SB:PtenNull PtenNull
Prostate tumor 21/21 21/21
Lung metastasis (P = 0.0207) 6/21 0/21
Lymph node metastasis (P = 0.0004) 15/21 3/21
Total number of mice = 21 per cohort (Fisher exact test).
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(P = 0.0005; Dataset S5). RNA-Seq expression data also dem-
onstrated up-regulated expression of Pparg and associated genes
(Table 2). Consistent with enhanced cholesterol and fatty acid
biosynthesis, PpargINT tumors had enhanced Oil Red O staining,
signifying increased levels of triglycerides and cholesterol esters
(Fig. 2F; Mann–Whitney, P < 0.001). When we looked at the
RNA-seq data, we observed that the PpargINT tumors had an
increased basal phenotype compared with the PpargWT and
PtenNull tumors (Fig. S3B), in keeping with a more aggressive
phenotype (15). To rule out the effect of the transposon on genes
adjacent to Pparg, we could not demonstrate any differentially
expressed genes within a 200-kb flanking region around the Pparg
locus in those tumors with insertions at this locus (PpargINT) [false
discover rate (FDR)-corrected Wald test, P < 0.001; P value
represents the likelihood (less than 1 in 1,000 chance) of another
differentially expressed gene being found flanking a 200-kb re-
gion on either side of Pparg]. As demonstrated previously (16),
this suggests that transposon insertions influence the expression
of genes within close proximity to where they insert, a behavior
distinct from retroviruses that can effect genes at distal sites.
When the whole cohort was analyzed, the PpargINT tumors
demonstrated increased levels of proliferation compared with
the PpargWT cohort (n = 8 vs. 13; Mann–Whitney, P = 0.0008;
Fig. 2G). Indeed, when we looked at the survival between the
cohorts, we found that the PpargINT subset exhibited significantly
accelerated prostate tumorigenesis compared with the PpargWT
cohort (median, 231 vs. 332 d; log-rank, P < 0.0001; Fig. 2H).
We next looked at PPARG expression in a number of human
CaP cell lines (Fig. S4A). PC3 and PC3M cells (which are PTEN
deficient) demonstrated elevated levels of PPARG at both the
protein and mRNA level compared with the other cell lines (Fig.
S4 A and B). Using a highly selective and irreversible inhibitor of
PPARG, GW9662 (17), we observed significant inhibition of
proliferation (WST-1; Mann–Whitney, P < 0.05), colony for-
mation (Mann–Whitney, P < 0.0001), and migration (in wound
scratch assay) (ANOVA, P < 0.001) in GW9662-treated PC3
cells (Fig. S4 C–E). To further validate data from the use of
GW9662, we carried out siRNA-mediated gene silencing of
PPARG in PC3, PC3M, and DU145 cells. We confirmed that
PPARG expression was reduced at the protein and mRNA
(by >70%) level (Fig. 3A and Fig. S4 F and G). Supporting data
from GW9662 treatment, siRNA knockdown of PPARG in PC3,
PC3M, and DU145 cells significantly suppressed cell pro-
liferation (Mann–Whitney, P < 0.01; Fig. 3B and Fig. S4H) and
migration at 24 h (ANOVA, P < 0.001; Fig. 3C and Fig. S4 I and J).
In addition, colony-forming assays demonstrated a reduction in the
number of colonies with siRNA treatment of PC3 cells (Mann–
Whitney, P < 0.0001; (Fig. S4 K and L). We next investigated the
role that down-regulation of PPARG activity had on its tran-
scriptional activity using an ELISA. We found that down-regu-
lation of PPARG using the GW9662 compound reduced the
transcriptional activity of PC3 and PC3M cells in a statistically
significant fashion (Fig. 3D).
To confirm that PPARG was responsible for the observed
phenotype, we next transiently overexpressed PPARG in DU145
cells, which have low basal levels of PPARG (Fig. S4 A and B).
This up-regulation of PPARG resulted in an increase in levels of
FASN (Fig. S4M), and enhanced proliferation (Mann–Whitney,
P < 0.001) and migration (at 18 h; ANOVA, P < 0.01) compared
with the empty vector controls (Fig. S4 N and O).
The in vivo effects of GW9662 were tested in a PC3 orthograft
model, whereby ∼7 million PC3 cells were injected into the an-
terior prostate of individual mice. GW9662 treatment was started
2 wk later when the tumors became palpable. Mice were then culled
after 4 wk of treatment. There was a trend (nonsignificant) toward
inhibition of tumor growth with GW9662 treatment compared with
vehicle control cohort (Fig. S5 A–C). There were, however, statis-
tically significant reductions in Ki-67 (Fig. 3 E–G; P < 0.0001)
and FASN expression (Fig. 3 H–J and Fig. S5D; P = 0.0004).
Importantly, there was a significant reduction in the number of
positive Pan-CK cells observed in the pelvic/para-aortic lymph
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Fig. 2. Characterization of SB:PtenNull tumors reveals oncogenic role for
Pparg. (A) RT-PCR for Pparg1 expression in PtenNull, PpargWT, and PpargINT
(n = 3, *P < 0.0001; Mann–Whitney). (B) Representative immunoblotting of
PPARG and FASN in PtenNull, PpargINT, and PpargWT. (C) PPARG and (E) FASN
quantification of staining using histoscore in PtenNull, PpargWT, and PpargINT,
respectively, demonstrating a statistically significant increase in protein
levels in PpargINT mice (n = 5, *P < 0.005 and *P < 0.0001, respectively;
Mann–Whitney). (D) PCR analysis for mRNA expression of Pparg and genes
encoding downstream lipogenic enzymes (Acc, Acly, and Fasn; n = 3, error
bars represent SEM, *P < 0.05; Mann–Whitney). (F) Oil Red O staining
quantification of triglyceride and cholesterol esters in snap frozen prostate
tumors of PpargWT and PpargINT samples (n = 3 vs. 3, error bars represent
SEM, *P < 0.001; Mann–Whitney). (G) Quantification of Ki-67–positive cells in
PpargINT demonstrated increased levels of proliferation compared with
PpargWT tumors (n = 8 vs.13, *P = 0.0008; Mann–Whitney). (H) Kaplan–Meier
(log-rank) curve demonstrating reduced survival in the PpargINT compared
with the PpargWT mice (*n = 8 vs.13, P < 0.0001).
Table 2. Expression of selected genes related to Pparg
insertions in the regulation of cholesterol and fatty
acid metabolism
Gene symbol PpargINT vs. PpargWT fold change Adjusted P value
Pparg 5.378 0.0085
Ppargc1b 2.311 0.0403
Rxra 2.170 0.0106
Srebf1 1.620 0.0110
Srebf2 1.739 0.0167
Data are extracted from the RNA-Seq dataset comparing PpargINT vs.
PpargWT prostate tumors (Dataset S4).
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nodes of the GW9662 treated cohort, suggesting a substantial
reduction in the metastatic burden (P < 0.0001; Fig. 3 K–M).
PPARG Expression Level Correlates with PTEN Loss and FASN Expression
in Human CaP and Confers a Poor Prognosis. Using our previously
published tissue microarray (TMA; n = 229) to investigate the
expression of PPARG in CaP (6), we found that the expression of
both PPARG and FASN was up-regulated in CaP (primary
Gleason grades 3–5) compared with the benign prostatic hy-
perplasia (BPH) control cohort (Fig. 4 A–F). In terms of coex-
pression, we were able to demonstrate significant correlations
between up-regulated expression of PPARG with low PTEN ex-
pression (below the median; Pearson correlation coefficient, r =
0.247, P < 0.0001) and up-regulation of pAKT (r = 0.291, P <
0.0001; Table 3 and Fig. S6 A–D) (6). Interestingly, we found the
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Fig. 3. Down-regulation of PPARG reduces proliferation and invasion
in vitro and lymph node metastasis in an in vivo prostate orthograft model.
(A) Immunoblotting for PPARG, FASN, and ACC in PC3 cells demonstrating
reduction of PPARG protein expression following siRNA, along with its ef-
fects on FASN and ACC expression. (B) Following siRNA-mediated knock-
down of PPARG expression (controlled with NTsiRNA), PC3 cells were
functionally assessed using (B) WST-1 proliferation assay, demonstrating
reduced growth (n = 3, error bars represent SEM, *P < 0.01; Mann–Whitney),
and (C) wound scratch assay, demonstrating reduced migration (n = 3, error
bars represent SD, P < 0.001; ANOVA). (D) ELISA-based PPARG transcription
reporter assay demonstrating that GW9662 treatment (20 and 50 μM) re-
duced PPARG transcriptional activity in PC3 and PC3M cells compared with
DMSO controls (n = 3, error bars represent SEM, *P < 0.01; Mann–Whitney).
Dotted red line signifies the background signal level. (E and F) Representa-
tive IHC staining and (G) boxplot of quantification of Ki-67 staining between
vehicle control and GW9662-treated PC3 orthotopic prostate tumors (n = 6
vs. 6, 20× magnification, three fields per mouse, *P < 0.0001; Mann–Whit-
ney). (H and I) Representative IHC staining and (J) boxplot quantification of
FASN staining between vehicle control and GW9662-treated PC3 orthotopic
prostate tumors (n = 6 vs. 6, 20× magnification, three fields per mouse, *P =
0.0004; Mann–Whitney). (K and L) Representative IHC staining and (M)
boxplot quantification Pan-CK staining in the lymph nodes between vehicle
control and GW9662-treated PC3 orthograft-bearing mice (n = 6 vs. 6, 20×
magnification, three fields per mouse, *P < 0.0001; Mann–Whitney). (Red
bar, 200 μm.)
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Fig. 4. Kaplan–Meier survival analysis of patients with CaP showing PPARG
and FASN up-regulation along with low levels of PTEN. Representative im-
ages of IHC for (A and B) PPARG and (C and D) FASN in human BPH and CaP.
(Red bar, 100 μm.) Boxplots representing histoscores of (E) PPARG and (F)
FASN in BPH and primary Gleason grade 3–5 CaP. Kaplan–Meier (log-rank
test) survival curves of CaP patients on a background of low PTEN levels
(below the median) with (G) high expression (above median) of PPARG
[compared with low (below median) PPARG; P = 0.0015] and (H) high ex-
pression (above median) of FASN [compared with low (below median) FASN;
P = 0.0006]. On a background of high pAKT level (above the median), (I) high
expression (above median) of PPARG [compared with low (below median)
PPARG; P = 0.0198] and (J) high expression (above median) of FASN [com-
pared with low (below median) FASN; P = 0.0047].
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strongest correlation between up-regulation of both PPARG and
FASN levels (Pearson correlation coefficient, r = 0.415, P <
0.0001; Table 3).
Disease-specific survival (DSS) in this cohort (n = 98/199
patients died of CaP) demonstrated no individual association
with up-regulation of PPARG, FASN, and pAKT or low PTEN
status when analyzed in isolation. In addition, up-regulated
PPARG or FASN on a high PTEN or low pAKT background
made no difference to DSS (Fig. S6 E–H). However, patients
who had up-regulated PPARG expression with low PTEN had a
marked reduction in DSS compared with those patients with only
low PPARG (median, 2.05 vs. 7.05 y; P = 0.0015; Fig. 4G).
Similarly, patients with up-regulated PPARG expression with
high pAKT had a reduced DSS (median, 2.09 vs. 6.32 y; P =
0.0198; Fig. 4I). In keeping with a functional link between
PPARG and FASN, up-regulated FASN expression on both a
low PTEN and high pAKT background was also associated with
shorter DSS (median, 1.91 vs. 7.49 y; P = 0.0006, and median,
2.045 vs. 6.2 y; P = 0.0047, respectively; Fig. 4 H and J).
Discussion
Prostate cancer remains a significant health problem worldwide,
being the most common solid organ cancer among men and
second only to lung cancer as a cause of cancer-related death in
males. CaP in humans is thought to arise via an accumulation of
mutations in tumor related genes transforming benign prostatic
epithelium to HGPIN that progresses to overt disease and sub-
sequent metastasis. In this study, patients with CaP that have low
levels of PTEN (or activation of pAKT) and accompanying
PPARG (or FASN) overexpression in their prostates appear to
have a poorer prognosis. In isolation, neither factor alters sur-
vival of CaP patients. In the mouse, Pparg activating mutations,
on a background of Pten deletion, accelerates prostate carcino-
genesis to result in metastatic disease, with associated up-regulated
expression of proteins involved in lipid metabolic pathways. Im-
portantly, treatment of a PC3 orthograft model with a PPARG
inhibitor appears to negate the effects of activated PPARG, re-
storing the PTEN loss-induced phenotype. Additional validation
could include use of a transgenic Pten null model that has prostate-
specific Pparg overexpression.
A recent sequencing study of 218 CaPs found inactivating
mutations in PTEN in 4% of primary and 42% of metastatic
tumors (3). When the authors examined the entire PI3K pathway
(including loss of the tumor suppressors PHLPP and INPP4B,
as well as activation of the PI3KCA gene itself), the PI3K path-
way was deregulated in 42% of primary tumors and in all me-
tastases (3). Another recent multi-institutional sequencing study
revealed somatic alteration in 49% (73/150) of the metastatic
castrate-resistant prostate cancer cases (4). Therefore, within
human CaP, deregulation of PI3K signaling appears essential for
prostate cancer progression. Certainly in the murine context, it
appears, from our data, to be vital as a “driver” mutation to
instigate tumorigenesis.
PPARG is a ligand-activated transcription factor, belonging to
the nuclear hormone receptor family (18). On activation by a
variety of natural/synthetic PPARG agonists, heterodimerization
with the retinoic acid receptor (RXR) occurs, followed by nuclear
translocation of the complex where it initiates target gene tran-
scription through binding to the peroxisome proliferator response
element (PPRE) (18). PPARG has been implicated in adipocyte
differentiation, functioning as a critical link between lipid and
carbohydrate metabolism (19). The role of PPARG1 (isoform 1)
role in cancer biology is poorly characterized, with both tumor
suppressing and oncogenic effects reported (20, 21). PPARG2
(isoform 2) is expressed at negligible levels in murine tumors and
human cell lines, at both the mRNA and protein levels (18).
CaP cell lines and clinical specimens exhibit elevated levels of
PPARG (22, 23). Paradoxically, it appears that PPARG activa-
tion using synthetic ligands (at high concentrations) suppresses
in vitro growth in LNCaP, DU145, and PC3 prostate cancer
cell lines and in vivo s.c. PC3 growth (20, 24, 25). However,
recent evidence suggests these agonists may act via a PPARG-
independent manner to induce cell cycle arrest and apoptosis
in CaP (24).
Recent work demonstrates that loss of Pparg coactivator 1α
(Pgc1α) is protective in chemical-induced colon and liver carci-
nogenesis in mice, with Pgc1α activation inducing expression of a
gene profile (Acly, Acc, and Fasn) that promotes conversion of
glucose into fatty acids to support tumorigenesis (26). In our
RNA-Seq data we demonstrated enrichment of Pparg-coac-
tivator 1β. It is well known that lipogenesis is a crucial factor for
prostate cancer development and progression, predominantly
through the enzymes ACLY, ACC, and FASN (27).
Our data are consistent with data on clinical CaP from cBio
portal (www.cbioportal.org): PPARG gene amplification was
found in 26% advanced CaP specimens. Interestingly, the enzyme
15-lipoxygenase-2 (15-LOX-2), which synthesizes 15-S-hydrox-
yeicosatetraenoic acid (15-S-HETE), an endogenous ligand of
PPARG (28), was found up-regulated in a further 17% (Fig. S7).
In total, one half of all sequenced tumors demonstrate up-regu-
lation of one or more of the lipid synthesis genes (FASN, ACC,
ACLY). Confirming our TMA data, if one or more of these genes
is altered, there is a reduction in DSS [Memorial Sloan Kettering
Cancer Centre (MSKCC) cohort; P = 0.0181; Fig. S7].
In summary, we demonstrate that PPARG up-regulation in
a PTEN-null background will cause more aggressive tumori-
genesis compared with PTEN-null tumors, with changes in ex-
pression of enzymes involved in lipid synthesis pathways. Knockdown
and inhibition of PPARG appears to reduce tumorgenesis both
in an in vitro and in vivo setting, whereas overexpression of
PPARG results in a more aggressive phenotype. Collectively, our
data suggest the possibility for targeted therapies using PPARG/
FASN inhibitors in this CaP patient subgroup (low PTEN/high
pAKT expression).
In addition, to our knowledge, we are the first to demonstrate
the strength of the SB transposon model system in successfully
determining low-frequency somatic mutations that may drive
prostate tumorigenesis. We envisage that this type of screen
could provide a useful platform to identify putative driver events
in both castration- and chemotherapy-resistant CaP.
Materials and Methods
Mouse Strains. All murine experiments were approved by the Animal Welfare
and Ethical Review Board (AWERB) at the University of Glasgow. Further
information is given in SI Materials and Methods.
CIS Analysis. Information is given in SI Materials and Methods.
RNA Extraction. Total RNA was extracted from frozen mouse prostate tu-
mors from PtenNull mice and SB:PtenNull mice with (PpargWT) and without
(PpargINT) Pparg insertions and from human CaP cell lines using the RNeasy
Mini Kit (QIAgen; 74104) according to the manufacturer’s instructions.
RNA quantity and quality were evaluated by spectrophotometry using
the NanoDrop 2000 spectrophotometer (Thermo Scientific) and 2100
Bioanalyzer (Agilent) RNA electropherograms, with calculation of RNA
integrity number (RIN).
Table 3. Association between the expression of PPARG and
PTEN/pAKT/FASN in clinical prostate cancer in our previously
published TMA (n = 229) (6)
Protein expression Pearson correlation coefficient P value
PPARG and low PTEN 0.247 <0.0001
PPARG and pAKT 0.291 <0.0001
PPARG and FASN 0.415 <0.0001
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Quantative Real-Time PCR. Information is provided in SI Materials and
Methods.
Library Preparation and Sequencing.Mouse RNA samples were processed using
the Illumina RNA-Seq protocol (Illumina) according to manufacturer’s instruc-
tions without poly(A) mRNA selection. The libraries were prepared using the
Illumina TruSeq stranded mRNA kit. Steps include poly(A) selection, fragmen-
tation, cDNA synthesis, A tail, adapter ligation and library amplification. The
amplified library was sequenced on the Nextseq 500 (Illumina) with a paired-
end sequencing strategy. The read length was set at 75 nt with an expected
library size of 200 bp (library size from the bioinformatic side would be the
mean number of reads per sample and that is just over 61 million).
Bioinformatics. Further information is given in SI Materials and Methods.
IHC. IHCwas performed on formalin-fixed, paraffin-embedded (FFPE) samples
(details in SI Materials and Methods).
Microscopy. Light microscopy was carried out using the Olympus BX51.
Human TMA. We studied FFPE sections from 229 prostate cancer patients (6).
Further information is given in SI Materials and Methods.
Immunoblotting. Western blotting was performed with the following anti-
bodies (dilutions as per datasheets): PTEN (Cell Signaling #9559), PPARG (Cell
Signaling #2435), FASN (Cell Signaling #3180), ACC (Cell Signaling #3676),
ACLY (Cell Signaling #4332), GAPDH (Sigma #G9295), and actin (Cell Sig-
naling #4968). Proteins were separated by SDS/PAGE and transferred by
semidry blotting onto a PVDF membrane (Immobilon-P; Millipore). Secondary
HRP-linked antibodies were used in conjunction with Pierce ECL Plus Western
Blotting Substrate (32132; Thermo Scientific). Further information is given in SI
Materials and Methods.
Oil Red O Staining. Further information is given in SI Materials and Methods.
Cell Culture. Human prostate cancer cell lines LnCaP, CRW22, PC3, PC3M, and
DU145 were authenticated by LCG standards and grown in RPMI (Gibco) con-
taining 10% (vol/vol) serum supplement and 2 mM L-glutamine at a temperature
of 37 °C with 5% (vol/vol) CO2.
GW9662 Inhibitor Treatment. Further information is given in SI Materials and
Methods.
Statistics. All statistical analyses (namely Mann–Whitney, Pearson correla-
tion coefficient, ANOVA, t test, and Kaplan–Meier survival analysis) were
performed using GraphPad Prism v5.0c. In the box whisker plots, whiskers
represent minimum and maximum, and the box represents the 25th and
75th percentiles.
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